Litigation Details for In Re: Application of Biogen MA, Inc. for issuance of a subpoena under 28 U.S.C. § 1782 (D. Del. 2023)

✉ Email this page to a colleague

Docket	⤷ Try a Trial	Date Filed	2023-05-15
Court	District Court, D. Delaware	Date Terminated	2023-05-22
Cause	28:1782 Letter rogatory - appointment	Assigned To	Gregory B. Williams
Jury Demand	None	Referred To
Parties	SANDOZ, INC.
Patents	10,119,976
Attorneys	Samantha G. Wilson
Firms	Young, Conaway, Stargatt & Taylor LLP
Link to Docket	External link to docket

The biologic drug covered by the patent cited in this case is ⤷ Try a Trial .

Subscribe to access the full database, or Try a Trial
Date Filed	Document No.	Description	Snippet	Link To Document
2023-05-15	3	Memorandum in Support	,794, 10,119,976, and 10,677,803 cover subject matter similar to EP 792 and relate to methods of evaluating…asserts 17 US patents. None of these patents are in the same family as EP 792. However, US Patents 11,280,794…. C. Biogen’s Assay Patents. Biogen owns several patents relating to methods of evaluating… a European patent (“EP 792”) and a divisional application pending in the European Patent Office are …and UK Patent Litigation and the Need for Further Discovery Biogen has asserted patents related	External link to document
2023-05-15	4	Declaration	US 11 280 794, US 10 119 976 and US 10 677 803 are granted US patents asserted by Biogen against…BIOGEN’S JCV ASSAY PATENTS 19. Biogen is the proprietor of a number of patents relating to methods…assays. The patents relevant to this application are described below. European Patent No. 3 575…the European Patent Office (“EPO”) (i.e. a “child” of the EP 792 “parent” patent). This application…initially identifying 28 patents as infringed, before narrowing to 17 patents. Biogen also filed an	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document